AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7733032
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of vitamin A
Trial: 18762597
Drug: Standard medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medication counseling
Trial: 25604346
Drug: Bromelain (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain (1000 mg·day(‐1))
Trial: 17352404
Drug: Tobramycin inhalation
RxNorm normalized name: Tobramycin Inhalation Powder
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin inhalation powder (TIP), 4 capsules of 28 mg (total 112 mg)
Trial: 17352404
Drug: Tobramycin solution
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tobramycin solution for inhalation (TSI), 300 mg
Trial: 16286669
Drug: EVA (560
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EVA (560 mg/d)
Trial: 7622632
Drug: Oral hygiene
RxNorm normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hygiene and scaling
Trial: 7622632
Drug: Full initial
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Full initial therapy including root planning
Trial: 2645848
Drug: Dextroamphetamine sulfate
RxNorm normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextroamphetamine sulfate (0.5 mg/kg/d)
Trial: 2645848
Drug: Fenfluramine hydrochloride
RxNorm normalized name: fenfluramine hydrochloride
DrugBank: Fenfluramine (DB00574)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine hydrochloride (0.6 mg/kg/d increased to 2.0 mg/kg/d)
Trial: 353461
Drug: Stenoptin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stenoptin (1 tablet 3 times per day for 8 weeks, then reduced to 1 tablet twice per day)
Trial: 353461
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 tablet 3 times per day for 8 weeks, then reduced to 1 tablet twice per day)
Trial: 28155333
Drug: Zofenopril 30-60
RxNorm normalized name: zofenopril 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zofenopril 30-60 mg daily
Trial: 28155333
Drug: Lisinopril 5-10
RxNorm normalized name: lisinopril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril 5-10 mg daily
Trial: 21793387
Drug: Jin's 'Sanzhen'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jin's 'Sanzhen' therapy
Trial: 21793387
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Jin's 'Sanzhen' therapy and rehabilitation training
Trial: 10795118
Drug: epirubicin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin 90 mg/m2-paclitaxel 175 mg/m2; 4 cycles bi-weekly, supported by G-CSF 5 micrograms/kg day 5-13 and 3 sequential cycles of CMF 600/40/600 mg/m2 at 2-weeks interval
Trial: 10795118
Drug: epirubicin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epirubicin 90 mg/m2-cyclophosphamide 600 mg/m2; 4 cycles tri-weekly, and 3 sequential cycles of CMF 600/40/600 mg/m2 at 3-weeks interval
Trial: 1549937
Drug: oral clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral clonidine 300 micrograms 120 min before surgery
Trial: 1549937
Drug: oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral diazepam 0.15 mg/kg 120 min before surgery
Trial: 29232560
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 1 g administered preoperatively
Trial: 29232560
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 1 g administered preoperatively in women
Trial: 29232560
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (TXA) 1 g administered preoperatively in men
Trial: 21196081
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse treatment initiation and engagement
Trial: 21196081
Drug: Substance abuse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substance abuse treatment engagement
Trial: 18958548
Drug: Group H
RxNorm normalized name: Prostaglandin group H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group H (prednisolone > or =10,000 mg)
Trial: 18958548
Drug: Group L
RxNorm normalized name: Blood group Lewis alpha-4-fucosyltransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group L (prednisolone <10,000 mg)
Trial: 1576099
Drug: nifedipine-SR (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine-SR (10 mg b.i.d)
Trial: 31097338
Drug: 20% albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% albumin fluid bolus therapy
Trial: 31097338
Drug: Crystalloid fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crystalloid fluid bolus therapy
Trial: 30315670
Drug: 100 mg/day
RxNorm normalized name: infigratinib phosphate 100 mg/day (100 mg x 1) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/day of DHEA for 28 days
Trial: 30315670
Drug: DHEA administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA administration
Trial: 22177821
Drug: Propofol-saline solution
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol-saline solution admixture (Group A - Control)
Trial: 20451469
Drug: Changes in
RxNorm normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Changes in neurotransmitters and biological response modifiers
Trial: 12818953
Drug: 1.0 mg
RxNorm normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg intranasal hydromorphone hydrochloride
Trial: 12818953
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg intranasal hydromorphone hydrochloride
Trial: 12818953
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg intravenous hydromorphone hydrochloride
Trial: 7960542
Drug: Nd-Yag laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd-Yag laser treatment
Trial: 7960542
Drug: Nd-Yag laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nd-Yag laser treatment combined with transurethral resection (TUR)
Trial: 29705707
Drug: Alcohol at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol at 60 mg/dL
Trial: 8157042
Drug: Intranasal glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal glucagon (2 mg)
Trial: 26884472
Drug: Intramuscular glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intramuscular glucagon (weight-based dose)
Trial: 26884472
Drug: Intranasal glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intranasal glucagon (2 mg and 3 mg)
Trial: 27403406
Drug: Dexamethasone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (4 mg/mL), administered via intratympanic injection, 0.5 ml, once every 2 days for 3 times
Trial: 27403406
Drug: Methylprednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (40 mg/mg), administered via intratympanic injection, 0.5 ml, along with bicarbonate
Trial: 22833175
Drug: Selective head-cooling
RxNorm normalized name: Head & Shoulders
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective head-cooling treatment (therapeutic hypothermia)
Trial: 22833175
Drug: Control (rectal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (rectal temperature 37°C)
Trial: 16759927
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone patches (300 microg T daily)
Trial: 15025600
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg kg(‐1) of aminophylline
Trial: 11708704
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (20 g per day for 6 days)
Trial: 10380782
Drug: Perfume exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perfume exposure during eye exposure (with fresh air inhaled)
Trial: 28333318
Drug: Oral dydrogesterone
RxNorm normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dydrogesterone 30 mg daily (10 mg three times daily)
Trial: 28333318
Drug: Micronized vaginal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronized vaginal progesterone (MVP) 600 mg daily (200 mg three times daily)
Trial: 23039088
Drug: Topiramate (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topiramate (100 mg twice daily)
Trial: 26035251
Drug: Nitroprusside administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroprusside administration
Trial: 3492950
Drug: Trimethoprim-sulfamethoxazole, 320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethoprim-sulfamethoxazole, 320 mg/d-1600 mg/d for 2 or 6 weeks
Trial: 3492950
Drug: Ampicillin, 2
RxNorm normalized name: Ampicillin, 250 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin, 2 g/d for 2 or 6 weeks
Trial: 24973959
Drug: Afatinib (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Afatinib (40 mg once daily)
Trial: 24973959
Drug: Methotrexate (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (40 mg/m2 once weekly)
Trial: 12615792
Drug: Azimilide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azimilide (100 to 125 mg once daily for 6 or 9 months)
Trial: 10228046
Drug: rhumAb-E25 infusions
RxNorm normalized name: RHUMAB-E25
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: rhumAb-E25 infusions biweekly for 46 weeks
Trial: 10228046
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of rhumAb-E25 infusions
Trial: 31202210
Drug: Manual therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual therapy combined with cryotherapy (MT-C)
Trial: 28644246
Drug: In-hospital exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-hospital exercise intervention during neoadjuvant chemotherapy
Trial: 24474552
Drug: Red Bull
RxNorm normalized name: acid red 35
DrugBank: Pantothenic acid (DB01783)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red Bull (355 mL)
Trial: 24474552
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water (355 mL)
Trial: 21961239
Drug: Local injection
RxNorm normalized name: Sclerosing agents for local injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local injection of 2 ml of 80,000 U gentamycin + 2 ml of lidocaine, twice a week for 3 weeks
Trial: 21961239
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline + 2 ml of lidocaine, twice a week for 3 weeks (Control Group B)
Trial: 21961239
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline + 2 ml of lidocaine, twice a week for 3 weeks (Control Group C)
Trial: 17344487
Drug: Medium Calcium
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium Calcium meal (MC meal: 84 mg/MJ)
Trial: 17344487
Drug: High Calcium
RxNorm normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Calcium meal (HC meal: 172 mg/MJ)
Trial: 17344487
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate supplement (Suppl meal: 183 mg/MJ)
Trial: 2444241
Drug: Extradural administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extradural administration of meptazinol 90 mg
Trial: 2444241
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) administration of meptazinol 90 mg
Trial: 26391263
Drug: Combined TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined TXA (1 g IV + 2 g local)
Trial: 26391263
Drug: IV TXA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV TXA (1.5 g)
Trial: 26391263
Drug: Local TXA
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local TXA (3 g)
Trial: 10817726
Drug: AMD-3100 intravenous
RxNorm normalized name: AMD
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMD-3100 intravenous infusion at 10, 20, 40, or 80 microg/kg
Trial: 10817726
Drug: AMD-3100 subcutaneous
RxNorm normalized name: AMD
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMD-3100 subcutaneous injection at 40 or 80 microg/kg
Trial: 10817726
Drug: AMD-3100 oral
RxNorm normalized name: AMD
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMD-3100 oral dosing at 80 and 160 microg/kg
Trial: 10817726
Drug: AMD-3100 intravenous
RxNorm normalized name: AMD
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMD-3100 intravenous dose at 80 microg/kg
Trial: 10817726
Drug: AMD-3100 intravenous
RxNorm normalized name: AMD
DrugBank: Methyldopa (DB00968)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AMD-3100 intravenous dose
Trial: 8877991
Drug: Octreotide 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 0.10 mg
Trial: 8877991
Drug: Octreotide 0.05
RxNorm normalized name: octreotide 0.05 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 0.05 mg
Trial: 8877991
Drug: Octreotide 0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide 0.10 mg and 0.05 mg
Trial: 1839442
Drug: Diltiazem (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (30 mg three times daily)
Trial: 28492790
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard therapy only)
Trial: 29291429
Drug: Phytosterols (PS,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterols (PS, 2 g/d)
Trial: 29291429
Drug: Curcumin (CC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (CC, 200 mg/d)
Trial: 29291429
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PS and Curcumin (PS-CC, 2 g/d-200 mg/d)
Trial: 2071257
Drug: L-alpha-glycerylphosphorylcholine (L-alpha-GFC)
RxNorm normalized name: L-alpha-Glycerophosphorylcholine
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-alpha-glycerylphosphorylcholine (L-alpha-GFC)
Trial: 6395907
Drug: Relaxation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation treatment (modified PMR and imagery exercises)
Trial: 29661902
Drug: 0.45 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/d oral conjugated equine estrogen (oCEE)
Trial: 29661902
Drug: 50 μg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 μg/d transdermal 17β‐estradiol (tE2)
Trial: 26171861
Drug: 10 grams
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 grams of oral creatine/day
Trial: 20666269
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with amlodipine and fosinopril given in the morning and at bedtime (group A)
Trial: 20666269
Drug: Concomitant administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Concomitant administration of amlodipine and fosinopril in the morning (group B)
Trial: 18789680
Drug: Berberine plus
RxNorm normalized name: berberine
DrugBank: Berberine (DB04115)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Berberine plus radiation therapy
Trial: 18789680
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus radiation therapy
Trial: 12663231
Drug: Probucol 500
RxNorm normalized name: probucol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 500 mg daily for 6 months
Trial: 11115310
Drug: Sequential mail/telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential mail/telephone reminder group
Trial: 1465591
Drug: Norfloxacin (active
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Norfloxacin (active drug)
Trial: 6437343
Drug: Postoperative administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postoperative administration of FT‐207 suppository (Group A)
Trial: 6437343
Drug: Preoperative and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative and postoperative administration of FT‐207 suppository (Group B)
Trial: 26709596
Drug: Modified-release (MR)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified-release (MR) formulations of omecamtiv mecarbil (25 mg)
Trial: 26709596
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) formulation of omecamtiv mecarbil (25 mg)
Trial: 24828092
Drug: Conventional subunit
RxNorm normalized name: covid-19, protein subunit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional subunit vaccine (Agrippal S1; Novartis)
Trial: 24828092
Drug: MF59-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted vaccine (Fluad; Novartis)
Trial: 24828092
Drug: Intradermal vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal vaccine (IDflu15; Sanofi Pasteur)
Trial: 22183975
Drug: Aggressive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive treatment (methotrexate 0.5 mg/kg/week, etanercept 0.8 mg/kg/week, prednisolone 0.5 mg/kg/day tapered to 0 by 17 weeks)
Trial: 22183975
Drug: Methotrexate (same
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (same dosage as arm 1), etanercept placebo, and prednisolone placebo
Trial: 17760981
Drug: Standardised physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised physiotherapy treatment of advice and exercises for the arm and shoulder for three months
Trial: 17760981
Drug: Standardised physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised physiotherapy treatment
Trial: 12146772
Drug: Sustained Achilles
RxNorm normalized name: Bos taurus achilles tendon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained Achilles tendon stretches (3 minutes, 3 times daily)
Trial: 12146772
Drug: Intermittent Achilles
RxNorm normalized name: Bos taurus achilles tendon preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent Achilles tendon stretches (5 sets, 20 seconds each, 2 times daily)
Trial: 1035149
Drug: Oral tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracycline in combination with a topical sodium sulfacetamide-sulfur-hydro-cortisone lotion
Trial: 23861993
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (4 g/day for 12 months)
Trial: 21287196
Drug: Strength trained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength trained individuals (L(opt) 9.7% BW)
Trial: 21287196
Drug: Speed trained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Speed trained individuals (L(opt) 9.2% BW)
Trial: 21287196
Drug: Physically active
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physically active individuals (L(opt) 8.7% BW)
Trial: 21287196
Drug: Sedentary individuals
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sedentary individuals (L(opt) 8.0% BW)
Trial: 17451642
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (CBT) for CFS
Trial: 15483071
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g high‐isoflavone soy protein (SOY)
Trial: 11666130
Drug: Nadroparin calcium
RxNorm normalized name: nadroparin calcium
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadroparin calcium followed by adjunctive oral aspirin for 6 months
Trial: 2531901
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ramipril once daily for 7 days
Trial: 2531901
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 7 days